News – Alligator Bioscience

2026-02-12

Regulatory

Alligator Bioscience AB reports full year financial results for 2025 and for Q4 2025 and provides a business update

Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant up ...

2026-02-05

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno ...

2026-01-30

Regulatory

During January 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a resul ...

2026-01-09

Lund, Sweden – 9 January 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...

2026-01-07

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-22

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-19

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-09

Lund, Sweden – 9 Dec 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henliu ...

2025-12-03

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...